Published in Exp Ther Med on August 23, 2016
The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1982) 67.54
Pattern recognition receptors and inflammation. Cell (2010) 21.05
Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity (1999) 11.64
CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J (2002) 6.83
Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet (2009) 6.42
Systemic lupus erythematosus disease activity index 2000. J Rheumatol (2002) 6.11
A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet (2009) 5.75
Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature (2005) 5.72
Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet (2008) 4.33
B-lymphocyte contributions to human autoimmune disease. Immunol Rev (2008) 2.89
Macrophage differentiation-specific expression of NF-IL6, a transcription factor for interleukin-6. Blood (1992) 2.62
A20: linking a complex regulator of ubiquitylation to immunity and human disease. Nat Rev Immunol (2012) 2.47
Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev (2009) 2.30
Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med (2000) 2.16
Role of the CCAAT enhancer binding proteins (C/EBPs) in adipocyte differentiation. Biochem Biophys Res Commun (1999) 1.99
A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains. J Immunol (2009) 1.84
CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases. Expert Rev Mol Med (2009) 1.38
Regulation of C/EBPβ and resulting functions in cells of the monocytic lineage. Cell Signal (2012) 1.19
TLR7 and TLR9 in SLE: when sensing self goes wrong. Immunol Res (2012) 1.18
Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol (2011) 1.13
Multiple forms of C/EBP beta bind the EFII enhancer sequence in the Rous sarcoma virus long terminal repeat. Mol Cell Biol (1994) 1.10
A20-binding inhibitor of NF-κB (ABIN1) controls Toll-like receptor-mediated CCAAT/enhancer-binding protein β activation and protects from inflammatory disease. Proc Natl Acad Sci U S A (2011) 1.08
The pathology of T cells in systemic lupus erythematosus. J Immunol Res (2014) 1.08
CCAAT/enhancer binding proteins are critical components of the transcriptional regulation of hematopoiesis (Review). Int J Mol Med (1998) 1.05
Differential regulation of macrophage CCAAT-enhancer binding protein isoforms by lipopolysaccharide and cytokines. Cytokine (2000) 1.04
[A review of the effects of prolactin hormone and cytokine on the development and pathogenesis of autoimmune diseases]. Vnitr Lek (2010) 0.96
The role of cytokines in the pathogenesis of systemic lupus erythematosus - from bench to bedside. Nephrology (Carlton) (2013) 0.92
Role of interleukin-10 and interleukin-10 receptor in systemic lupus erythematosus. Clin Rheumatol (2013) 0.92
The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus. J Interferon Cytokine Res (2011) 0.91
Vascular endothelial growth factor blockade reduces plasma cytokines in a murine model of polymicrobial sepsis. Inflammation (2004) 0.91
Down-regulation of A20 mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. J Clin Immunol (2012) 0.90
TRAF activation of C/EBPbeta (NF-IL6) via p38 MAPK induces HIV-1 gene expression in monocytes/macrophages. Microbes Infect (2007) 0.86
Single nucleotide polymorphisms at the TNFAIP3/A20 locus and susceptibility/resistance to inflammatory and autoimmune diseases. Adv Exp Med Biol (2014) 0.84
Increased expression of Toll-like receptors (TLRs) 7 and 9 and other cytokines in systemic lupus erythematosus (SLE) patients: ethnic differences and potential new targets for therapeutic drugs. Mol Immunol (2014) 0.83
Transcription of Tnfaip3 is regulated by NF-κB and p38 via C/EBPβ in activated macrophages. PLoS One (2013) 0.83
Single-nucleotide polymorphism and haplotypes of TNIP1 associated with systemic lupus erythematosus in a Chinese Han population. J Rheumatol (2013) 0.80
Cell biology. Turning off inflammation signaling. Science (2010) 0.79
Differential interaction of nuclear factors with the PRE-I enhancer element of the human IL-4 promoter in different T cell subsets. J Immunol (1997) 0.79
Interleukin 1, interleukin 6, interleukin 10, and tumor necrosis factor α in active and quiescent systemic lupus erythematosus. J Investig Med (2014) 0.79
TNF inhibition in SLE: where do we stand? Lupus (2009) 0.79
Serum levels of three angiogenic factors in systemic lupus erythematosus and their clinical significance. Biomed Res Int (2014) 0.77
Lupus erythematosus. Part I: epidemiology, genetics and immunology. J Dtsch Dermatol Ges (2013) 0.77
Tumor necrosis factor α-induced protein-3 protects zinc transporter 8 against proinflammatory cytokine-induced downregulation. Exp Ther Med (2016) 0.77
Daphnetin inhibits inflammation in the NZB/W F1 systemic lupus erythematosus murine model via inhibition of NF-κB activity. Exp Ther Med (2016) 0.75